STOCK TITAN

Jazz Pharmaceuticals plc - JAZZ STOCK NEWS

Welcome to our dedicated news page for Jazz Pharmaceuticals plc (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jazz Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jazz Pharmaceuticals plc's position in the market.

Rhea-AI Summary
Jazz Pharmaceuticals to present 14 abstracts at World Sleep 2023 Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences
-
Rhea-AI Summary
Jazz Pharmaceuticals to present data on zanidatamab and Zepzelca at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
-
Rhea-AI Summary
Jazz Pharmaceuticals releases 2022 Corporate Sustainability and Social Impact Report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
Rhea-AI Summary
Jazz Pharmaceuticals to participate in three investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
Rhea-AI Summary
Renée Galá promoted to President and Chief Operating Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
management
Rhea-AI Summary
Jazz Pharmaceuticals presented data on oxybate's positive impact on sleep quality and architecture in narcolepsy patients. No significant difference in improvement was found between dosing schedules. Safety and efficacy of Xywav were similar in narcolepsy patients with and without psychiatric comorbidities. Idiopathic hypersomnia has a profound impact on patient quality of life, highlighting the need for effective treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
Rhea-AI Summary
Jazz Pharmaceuticals to participate in Citi Annual BioPharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
conferences
-
Rhea-AI Summary
Jazz Pharmaceuticals reports strong Q2 2023 results, with total revenues of $957 million. Net product sales of Xywav increased by 39% YoY, Epidiolex increased by 15% YoY, and Rylaze increased by 39% YoY. The oncology portfolio is expected to reach $1 billion in net product sales this year. Zanidatamab shows promise with upcoming late-stage data readouts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) to report 2023 second quarter financial results on August 9, 2023. Live webcast to discuss financial update and business performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences earnings
Jazz Pharmaceuticals plc

Nasdaq:JAZZ

JAZZ Rankings

JAZZ Stock Data

6.89B
60.45M
2.82%
95.89%
5.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About JAZZ

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni